SAB Biotherapeutics (SABS) announced that Lucy To has been named Chief Financial Officer effective August 12, 2024. To brings over 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company. Prior to joining SAB, she was a Managing Director in the Healthcare Investment Banking Group at Wells Fargo (WFC) where she advised biopharmaceutical companies on financing and strategic transactions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics management to meet with Oppenheimer
- SAB Biotherapeutics announces new name, SAB BIO for rebrand focus on type 1
- SAb Biotherapeutics Rebrands as SAB BIO
- SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
- SAB Biotherapeutics initiated with Buy on risk/reward at Brookline